Lymphomas
Upcoming SlideShare
Loading in...5
×
 
  • 1,841 views

lymphoma;TUMOR

lymphoma;TUMOR

Statistics

Views

Total Views
1,841
Views on SlideShare
1,841
Embed Views
0

Actions

Likes
0
Downloads
111
Comments
2

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Lymphomas Lymphomas Presentation Transcript

  • Lymphomas in the Mediastinum
  • Mediastinal Large B Cell Lymphoma
  • Mediastinal Large B Cell LymphomaCD20 CD30
  • Immunhistochemische Differentialdiagnose Nodale Diffuse MLBCL Large B Cell LymphomaCD20, CD79a +++ +++CD30, CD23 ----/+ +++IgM, Light chain ++ > ---- ----CD10 ++ > ---- ----HLA-DR +++ ----Bcl-6 +++/- ----
  • Mediastinal Large B Cell Lymphoma Möller, WHO 2004
  • Combined Hodgkin Lymphom & MLBCL CD30+CD15-CD20+CD30+CD15+CD20-
  • Hodgkin Lymphoma in a Mediastinal Lymph Node CD30
  • Hodgkin Lymphoma in the ThymusCD30 CK19
  • Pseudoepitheliomatous Hyperplasia & Thymic Cysts CK19Search for Lymphoma, Thymoma, LCH, Metastasis, Germ Cell Neoplasia
  • Immunhistochemische Differentialdiagnose Hodgkin Lymphoma MLBCL (Classical Type; usually NS)CD30 +++ +++ > ----CD15 + > ---- -----CD20 -/+ +++CD79a ---- +++PanLeu (CD45) ---- +++
  • Borderline Casesbetween HL and Mediastinal Large B Cell Lymphoma ? YES !
  • Distinct Gene Expression Profile of MLBCL (PMBL)
  • Survival of MLBCL (PMBL) Patients
  • ConclusionsDistinct gene expression profile of PMBL(molecular diagnosis)PMBL patients are clinically distinctClose Relationship of PMBL to HodgkinLymphoma
  • DD between MLBCL and ALCL CD3 CD30 ALK-1
  • Immunohistochemical Differential Diagnosis Anaplastic Large Cell MLBCL LymphomaCD30 +++ +++ > ----CD15 ---- -----CD20, CD79a ---- +++CD3, CD5, CD43, TIA-1 -/++ -----ALK-1 -/++ -----
  • T-LBL des ThymusInfiltration of Mediastinum & Heart; Pleural Effusions; +/- Leukemia
  • Differential Diagnosis of B1/B2Thymom vs. T-LBL Thymom T-LBL Cytokeratin 19 CD1a Ki67
  • DD of Strongly Proliferative Mediastinal Processes Thymus Thymoma T-LBLKi67 not different between Normal Thymus, Thymoma and T-LBL
  • Lymphocyte Differentiation in the Thymus WHO, 2004
  • If there is no Abnormal Phenotype of Immature T cells Loss of CD1a, CD3, CD4, CD5, CD8 Overexpression of CD34 > CD10 JH-PCR is monoclonal in ~ 80% of T-LBL Cases
  • 42 Year-old Patient with Sjogren‘s Syndrome
  • No Cortico-medullary Differentiation, No Capsule
  • Germinal Center
  • MALT Lymphoma of the ThymusCD20+, CD5-, CD10-, CD23- κ
  • Lymphoepithelial Lesions in MALT-Lymphoma of the Thymus Cytokeratin 19 LEL
  • 78 year-old Female, No Symptoms, Progressibe Lymphocytosis Mediastinal Mass
  • What is Different Compared to the Previous Case? HC
  • No Germinal Centers !HC
  • Cytokeratin 19
  • CD3+, TdT(-)
  • Ki67 ~10%
  • Diagnosis : T-Prolymphocytic Leukemia (TPLL)
  • ConclusionAll Peripheral Lymphomas Can Occur in the Mediastinum
  • Clinical Relevance of the New WHO Classification?
  • Therapeutic Decisions in Thymoma Patients a) Masaoka Stage b) WHO Histotype c) Resection status 1,0 1,0 Stage 1 1,0 p < 0.05 Type A, AB, B1 ,9 Probability of Survival Probability of SurvivalProbability of Survival ,9 Stage 3 ,9 ,8 ,8 Stage 2 ,7 R0 resection ,7 ,8 ,6 Type B2 ,6 ,5 ,7 Type B3 ,5 ,4 R 1+2 resection Type C Stage 4 ,4 ,6 ,3 0 10 20 30 0 10 20 30 0 10 20 30 Survival (Years) Survival (Years) Survival (Years) JCO Cancer, 2003; J Clin Oncol, 2004
  • Therapeutic Decisions in Thymoma Patients Stage Histology OP, RX CHEM Resection Status
  • Therapeutic Decisions in Thymoma Patients A, AB, B1 B2, B3 Thymomas &Thymome (50%) Thymic Carcinomas (50%)Surgery (RO) Surgery Stage I Stage II Stage III/IV R1, R2Wait-and-See W&S ? Rx CHEMO Rx & Rx
  • C-KIT Expression in Thymic Carcinoma A ABB2 B3 SCC0/112 Type A-B2 1/28 Type B3 19/24 SCC
  • ma ma mo mo 1 2 3 T WT - WT - WT - MU thy thy T T IT IT KI KI CK CK B3 B2 5 6 CC CC CC CC ST pe pe C C Responder TS TS TS TS TS TS Ty Ty GI KIT(+) KIT(-)GIST Patient B., A. 100 c-KIT 100 phospho-c-KIT100 phospho-AKT 100 1 phospho-BAD 20 5 phospho-MAPK (p42+p44) 10 1 phospho-STAT-1 1001 phospho-STAT-3 Immunohistochemistry CD117 N.E.J.Med. 2004
  • Imatinib (-) Imatinib (+)
  • Summary• The new WHO Thymoma Classification describes histological, genetic und clinical entities• In addition to tumor stage and resection status, the histological thymoma subtype according to WHO criteria contributes significantly to therapeutic decisions in thymoma patients• Type A, AB and probably B1 thymomas even at stage II do not require any adjuvant treatment after R0-Resection
  • AcknowledgementsPhilipp Ströbel (all in Würzburg) DFGMasayoshi Inoue & W.-Y. ChuangAndreas Zettl DeutscheHans Konrad Müller-Hermelink KrebshilfeEuropean Thymoma NetworkPeter Rieckmann (Würzburg)Ralf Gold (Göttingen) EUWilfried Nix (Mainz) THYMAIDEBerthold Schalke (Regensburg)Reinhard Kiefer (Münster)Michael Semik (Münster)Francesco Scaravilli (London)Nick Willcox, Angela Vincent (Oxford) AlexanderPärt Peterson (Tartu) von Humboldt Foundation